Join Dr. Juan Pablo Torres Torretti for an instructive presentation on the real-world implementation and impact of nirsevimab for RSV prevention. Drawing from groundbreaking data from Chile—the first Southern Hemisphere country to implement a nationwide nirsevimab immunization program—Dr. Torres reveals remarkable outcomes including 80-95% reduction in RSV hospitalizations and 85% reduction in PICU admissions. The presentation highlights Chile's successful strategy of protecting both newborns and infants under six months, achieving over 90% coverage rates with an excellent safety profile. Dr. Torres also shares comparative data from other countries including Spain's NIRSE-GAL study, demonstrating consistent effectiveness across different healthcare systems and providing compelling evidence for nirsevimab's role in transforming RSV prevention globally.
